Lack of association between the interferon-α signature and longitudinal changes in disease activity in systemic lupus erythematosus

Abstract

The findings indicate that IFN-induced gene expression has limited clinical utility as a biomarker of acute changes in disease activity.

Type I interferon–mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy

“…In NZB/NZW lupus-prone mice, inhibition of Bcl-2, a necessary molecule for pDC survival, resulted in selectively depletion of pDCs and reduction of IFN- production (138). Furthermore, proteasome inhibitors (carfilzomib, bortezomib) managed to suppress the IFN- production by TLR-activated pDCs by inhibiting pDC survival and function in lupus mice models (139). More recently, the pDC inhibitory receptor BDCA-2 (CD303) has been used to block IFN-I production in pre-clinical studies (140).…”

Autoantibodies, complement and type I interferon as biomarkers for personalized medicine in SLE

“…61,62 Interestingly, this seems to be an exclusive phenomenon of the WBIFNS, since IFN-a, IP-10, CD64 and SIGLEC1 showed a longitudinal correlation over time. 11,31,57 The reasons for this discrepancy have not been addressed so far.…”

Interferon and Apoptosis in Systemic Lupus Erythematosus

“…Clinically, disease activity can be measured and correlated to other observations to determine the cause of the different levels of activity. One item linked to SLE activity is interferon, where higher levels of IFN in the serum correlated with more severe disease in most cases Dall'Era, et al, 2005;Feng, et al, 2006;Landolt-Marticorena, et al, 2009;Petri, et al, 2009;Zhuang, et al, 2005). Common autoantibodies also correlate with IFN levels.…”